Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cocrystal Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COCP
Nasdaq
2834
www.cocrystalpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cocrystal Pharma, Inc.
COCP: CDI-988 Data to be Presented at ICAR 2026
- Feb 23rd, 2026 5:31 am
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
- Feb 19th, 2026 6:00 am
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
- Dec 18th, 2025 6:00 am
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
- Dec 1st, 2025 6:00 am
COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26…
- Nov 18th, 2025 4:21 am
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- Nov 14th, 2025 6:00 am
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
- Oct 30th, 2025 6:00 am
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
- Oct 27th, 2025 6:00 am
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
- Oct 2nd, 2025 6:00 am
COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…
- Sep 17th, 2025 7:44 am
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Sep 15th, 2025 2:30 pm
BC-Most Active Stocks
- Sep 12th, 2025 8:30 am
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Sep 12th, 2025 7:43 am
Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report
- Sep 12th, 2025 7:21 am
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
- Sep 12th, 2025 6:00 am
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
- Sep 8th, 2025 6:00 am
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
- Sep 3rd, 2025 6:00 am
COCP: Norovirus Challenge Study to Initiate in 4Q25…
- Aug 19th, 2025 8:12 am
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- Aug 14th, 2025 6:00 am
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
- Aug 5th, 2025 6:00 am
Scroll